Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy

@inproceedings{Li2017PathologicalCR,
  title={Pathological complete response as a surrogate for relapse-free survival in patients with triple negative breast cancer after neoadjuvant chemotherapy},
  author={Junjie Li and Sheng Chen and Canming Chen and Genhong Di and Guangyu Liu and Jiong Wu and Zhimin Shao},
  booktitle={Oncotarget},
  year={2017}
}
We retrospective analyzed triple negative breast cancer (TNBC) patients who received either taxane-based or anthracycline-based neoadjuvant chemotherapy, evaluated whether pathological complete response (pCR) is a surrogate endpoint for relapse free survival (RFS) in TNBC and explored which subgroup of patients benefits more from superior treatment regimen. 186 patients received taxane-based (Group A) or anthracycline-based (Group B) neoadjuvant chemotherapy, median follow-up was 48.1 months… CONTINUE READING
Tweets
This paper has been referenced on Twitter 1 time. VIEW TWEETS

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

  • SL GvonMinckwitz, A Schneeweiss, +10 authors M. Untch
  • Oral presentation at: San Antonio Breast Cancer…
  • 2015
Highly Influential
5 Excerpts

Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/ or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)

  • DB WMSikov, CM Perou, +10 authors D Collyar
  • Oral presentation at: San Antonio Breast Cancer…
  • 2015
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…